The Kidney Disease: Improving Global Outcomes (KDIGO) guideline update 2024 recommends the use of SGLT2i in diabetic patients with CKD and GFR ≥ 20 ml/min/1.73 m2. In all other patients, regardless of diabetic status, SGLT2i are recommended for CKD patients with GFR ≥20 ml/min/1.73 m2 who either have a urine albumin-creatinine ratio (ACR) ≥20 mg/mmol, or have heart failure, irrespective of the degree of albuminuria. The gene discussed is ALB; the disease is chronic kidney disease.